Horizon Discovery Group PLC (LON:HZD)‘s stock had its “speculative buy” rating restated by research analysts at Beaufort Securities in a note issued to investors on Wednesday.

Other research analysts also recently issued research reports about the stock. N+1 Singer restated a “buy” rating and set a GBX 194 ($2.53) price target on shares of Horizon Discovery Group PLC in a research report on Tuesday. Panmure Gordon restated a “buy” rating and set a GBX 270 ($3.52) price target on shares of Horizon Discovery Group PLC in a research report on Thursday, September 1st. Finally, Numis Securities Ltd restated a “buy” rating and set a GBX 252 ($3.29) price target on shares of Horizon Discovery Group PLC in a research report on Wednesday, September 7th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of GBX 217.25 ($2.84).

Horizon Discovery Group PLC (LON:HZD) opened at 156.00 on Wednesday. Horizon Discovery Group PLC has a 12 month low of GBX 125.00 and a 12 month high of GBX 188.06. The stock’s market cap is GBX 146.78 million. The firm’s 50 day moving average price is GBX 160.21 and its 200 day moving average price is GBX 160.59.

Horizon Discovery Group PLC Company Profile

Horizon Discovery (LSE: HZD) is a world-leading gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. Horizon’s proprietary gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.

Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.